

RECEIVED

APR 30 2002

BY HAND DELIVERY

Sheet 1 of 3

TECH CENTER 1600/2900

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

9426-056

APPLICATION NO.

09/724,621

APPLICANT

Taylor et al.

FILING DATE

November 28, 2000

GROUP

1642

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
KAC	AA	5,985,847	11/16/99	Carson et al.			
KAC	AB	6,221,621	4/14/01	Kinders et al.			
KAC	BW	5,376,356	12/27/94	Morgan, Jr.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
KAC	AC	WO 98/39659	09/11/98	PCT				
	AD	WO 97/38136	10/16/97	PCT				
	AE	WO 96/37234	11/28/96	PCT				
	AF	EP 0448464	09/25/91	Europe				
	BX	WO 87/06344	10/22/87	PCT				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

KAC	AG	Castronovo V et al., 1989, "Possible role of human natural anti-Gal antibodies in the natural antitumor defense system, "J Natl Cancer Inst. 81(3):212-6.						
	AH	Clark JI et al., "Natural killer cell-directed bispecific antibodies", in <u>Bispecific Antibodies</u> , Fanger MW (ed.), RG Landis Co., Austin, pp. 77-88.						
	AI	de Gast GC et al., 1997, "Clinical perspectives of bispecific antibodies in cancer, "Cancer Immunol Immunother. 45(3-4):121-3.						
	AJ	Deo et al., 1998, J. of Immunol., 160: 1677 Abstract						
	AK	Desai PR et al., 1995, "Anti-Thomsen-Friedenreich (T) antibody-based ELISA and its application to human breast carcinoma detection, "J Immunol Methods. 188(2):175-85.						
	AL	Dodds and Sim (eds.), <u>Complement: A Practical Approach</u> , 1997, Oxford University Press.						
	AM	Edberg JC et al., 1988, "Quantitative analyses of the relationship between C3 consumption, C3b capture, and immune adherence of complement-fixing antibody/DNA immune complexes, "J Immunol. 141(12):4258-65.						
	AN	Gorter A et al., 1996, "Expression of CD46, CD55, and CD59 on renal tumor cell lines and their role in preventing complement-mediated tumor cell lysis, "Lab Invest. 74(6):1039-49.						
	AO	Gross DJ et al., 1988, "An immunochemical assay for natural IgM antibodies with an affinity to galactose and whose titer is reduced in the sera of cancer patients, "Eur J Cancer Clin Oncol. 24(3):363-7.						
	AP	Hakomori S, "Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism, "Cancer Res. 1996 Dec 1;56(23):5309-18.						
	AQ	Higuchi et al., 1980, "Natural humoral immunity in patients with malignant diseases", J Clin Lab Immunol. 4:141-143.						
	AR	Howard and Hughes Jones, 1988, <u>Monoclonal Antibody Therapy</u> , Vol. 45, p. 3						
	AS	Irie et al., 1975, "Demonstration of In Vivo Reaction of Anti Body and Complement to Human Cancer Cells by Mixed Hemadsorption", Proc. Amer. Assoc. Cancer Res. Vol 16, p. 170, Abstract						
	AT	Irie K et al., 1974, "Evidence for in vivo reaction of antibody and complement to surface antigens of human cancer cells, "Science. 186(4162):454-6.						
	AU	Jarvis GA et al., 1997, "Expression and function of the complement membrane attack complex inhibitor protectin (CD59) in human prostate cancer. Int J Cancer. 71(6):1049-55.						

RECEIVED

APR 30 2007

BY HAND DELIVERY

Sheet 2 of 3

KAL	AV	Maenpaa A et al., 1996, "Expression of complement membrane regulators membrane cofactor protein (CD46), decay accelerating factor (CD55), and protectin (CD59) in human malignant gliomas, "Am J Pathol. 148(4):1139-52.
	AW	Makrides SC et al., 1992, "Cell surface expression of the C3b/C4b receptor (CR1) protects Chinese hamster ovary cells from lysis by human complement, "J Biol Chem. 267(34):24754-61.
	AX	Mehta RL et al., 1986, "Binding and catabolism of aggregated immunoglobulins containing C3b by U937 cells, "J Immunol. 136(5):1765-71.
	AY	Michael et al., "Synthesis of iC3b/C3d and Expression of a CD21-Like Protein by Malignant Epithelium", Growth Factors and Receptors I: Abstract 2167
	AZ	Mollnes TE et al., 1987, "Activation of the third component of complement (C3) detected by a monoclonal anti-C3'g' neoantigen antibody in a one-step enzyme immunoassay, "J Immunol Methods. 101(2):201-7.
	BA	Neri et al., 1983, J. of Gynaecological Oncology, 4:37 Abstract
	BB	Niculescu F et al., 1992, "Persistent complement activation on tumor cells in breast cancer, "Am J Pathol. 140(5):1039-43.
	BC	Okada H and Baba T, 1974, "Rosette formation of human erythrocytes on cultured cells of tumour origin and activation of complement by cell membrane, " Nature. 248(448):521-2.
	BD	Paul et al., 1993, Immunology, Fundamental Immunology, 3 rd ed., Raven Press, NY, P. 934
	BE	Perlmann et al., 1982, "Interaction of Target Cell-Bound C3bi and C3d With Human Lymphocyte Receptors", J. Exp. Med. 153:1592-1603
	BF	Petronis JD et al., 1998, "Indium-111 capromab pendetide (ProstaScint) imaging to detect recurrent and metastatic prostate cancer, "Clin Nucl Med. 23(10):672-7.
	BG	Reiter et al., "Killing of Human Tumor Cells By Antibody C3b Conjugates and Human Complement", 119-135
	BH	Renner C et al., 1995, "Tumor therapy by immune recruitment with bispecific antibodies, "Immunol Rev. 1995 Jun;145:179-209.
	BI	Schlom et al. 1991, "Monoclonal Antibodies: They're more or less than you think", Molecular Foundations of Oncology, pp. 95-134
	BJ	Seegal BC et al., 1976, "Immunoglobulins, complement and foreign antigens in human tumor cells, "Int Arch Allergy Appl Immunol. 1976;52(1-4):205-11.
	BK	Segal DM et al., "T-cell targeted cytotoxicity" in Bispecific Antibodies, Fanger MW (ed.), RG Landis Co., Austin, pp. 27-42.
	BL	Springer GF, 1997, "Immunoreactive T and Tn epitopes in cancer diagnosis, prognosis, and immunotherapy, "J Mol Med. 75(8):594-602.
	BM	Springer GF, 1984, "T and Tn, general carcinoma autoantigens, "Science. 224(4654):1198-206.
	BN	Taylor RP et al., 1997, "Clearance of blood-borne pathogens mediated through bispecific monoclonal antibodies bound to the primate erythrocyte complement receptor, "Cancer Immunol Immunother. 1997 Nov-Dec;45(3-4):152-5.
	BO	Taylor RP et al., 1989, "Quantitative analyses of C3b capture and immune adherence of IgM antibody/dsDNA immune complexes, "J Immunol. 143(11):3626-31.
	BP	Taylor et al., 1991, "Use of heteropolymeric monoclonal antibodies to attach antigens to the C3b receptor of human erythrocytes: A potential therapeutic treatment", Proc. Natl. Acad. Sci. USA 88:3305-3309
	BQ	Thornton BP et al., 1996, "Function of C3 in a humoral response: iC3b/C3dg bound to an immune complex generated with natural antibody and a primary antigen promotes antigen uptake and the expression of co-stimulatory molecules by all B cells, but only stimulates immunoglobulin synthesis by antigen-specific B cells, "Clin Exp Immunol. 104(3):531-7.
	BR	Tosic L et al., 1989, "Preparation of monoclonal antibodies to C3b by immunization with C3b(i)-sepharose, "J Immunol Methods. 120(2):241-9.
	BS	Vetvicka V et al., 1999, "Regulation of CR3 (CD11b/CD18)-dependent natural killer (NK) cell cytotoxicity by tumour target cell MHC class I molecules, "Clin Exp Immunol. 115(2):229-35.
	BT	Vetvicka V et al., 1997, "Targeting of natural killer cells to mammary carcinoma via naturally occurring tumor cell-bound iC3b and beta-glucan-primed CR3 (CD11b/CD18), "J Immunol. 159(2):599-605.
	BU	Vetvicka V et al., 1996, "Soluble beta-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells, "J Clin Invest. 98(1):50-61.
	BV	Weisman HF et al., 1990, "Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis, "Science. 249(4965):146-51.
	BY	Campbell et al., 1994, "Mechanisms of Binding of Brucella abortus to mononuclear phagocytes from cows naturally resistant or susceptible to brucellosis", Veterinary Immun. And Immunopath. 41:295-306.
	BZ	Dempsey et al., 1996, "C3d of Complement as a Molecular Adjuvant: Bridging Innate and Acquired Immunity", Science 271:348-350.

✓	CA	Deo et al., 1998, "Bispecific molecules directed to the Fc receptor for IgA (Fc α RI, CD89) and tumor antigens efficiently promote cell mediated cytotoxicity of Tumor Targets in Whole Blood", J. Immun. 1677-1681
	CB	Emery and Harris, 1995, "Strategies for Humanizing Antibodies", Chapter 6, Antibody Engineering, 2 nd Ed., Oxford Univ. Press, pp. 159-160, 180-181
	CC	Huemer et al., 1993, "Herpes simplex virus glycoprotein C: Molecular mimicry of complement regulatory proteins by a viral protein", Immunol. 79: 639-647
	CD	McCormick et al., 1997, "Bispecific Antibodies Overcome the Opsonin-Receptor Mismatch of Cystic Fibrosis In Vitro", J. of Immun. 3476-3482.
	CE	Krettl et al., 1985, "Binding of C3 fragments to the Trypanosoma cruzi surface in the absence of specific antibodies and without activation of the complement cascade", Clin Exp Immunol. 62:270-277
	CF	Newman et al., 1985, "Deposition of C3b and iC3b onto particulate activators of the human complement system" J. Exp. Med. 161:1414-1431
	CG	Seya et al., 1990, "Complement-mediated tumor cell damage induced by antibodies against membrane cofactor protein (MCP, CD46)", J. Exp. Med. 172: 1673-1680
	CH	Tamerius et al., 1985, "Detection of a neoantigen on human C3bi and C3d by monoclonal antibody", J. of Immunol. 135:2015-2019.
✓	CI	Vaporciyan et al., 1993, "Enhanced Generation of O ₂ ⁻ by human Neutrophils via a complement eC3b/Mac-1 Interaction", Biol Signals 2:126-135.
EXAMINER <i>John A. Gaudin</i>		DATE CONSIDERED 1/27/05
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		



RECEIVED

MAY 29 2002

Express Mail N .: EL 477 036 532 US

Sheet 1 of 1

TECH CENTER 1600/2900

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)					ATTY. DOCKET NO.		APPLICATION NO.	
					9426-056		09/724,621	
					APPLICANT			
					Taylor et al.			
					FILING DATE		GROUP	
					November 28, 2000		1642	
U.S. PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)								
KAC	CJ	McCormick et al. Bispecific antibody (ANTI-C3d/60.3), compensates, in vitro, for the elastase-mediated opsonin-receptor mismatch cystic fibrosis. Immunotechnology Y. 1996, 2(4):303 (abstract)						
EXAMINER					DATE CONSIDERED			
Karen A. Gault					1/27/05			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

RECEIVED

JUN 25 2002

TECH CENTER 1600/300